Monday afternoon's analyst upgrades and downgrades included American Airlines, Biogen, Citigroup, EA, Gilead, Meta, Micron, Zscaler and more.
Barclays (LON:BARC) analyst Carter Gould maintained a Hold rating on Biogen (NASDAQ:BIIB) on Wednesday, setting a price target of $280, which is approximately 25.04% above the...
BEIJING (Reuters) - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be included in China's national medical insurance coverage in a new...
It has been a busy week for the biotech sector with drug approvals and other regular pipeline updates. The development of coronavirus treatments and subsequent progress also...
There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover,...
Today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the Nasdaq 100. Whether the strong start to November will...
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 170.70 | 171.28 | 168.34 | +5.38 | +3.25% | 46.85M | NASDAQ | |||
| 2,940.70 | 2,948.60 | 2,905.00 | +77.6 | +2.71% | 561.08K | NASDAQ | |||
| 324.63 | 326.54 | 321.00 | +6.76 | +2.13% | 6.76M | NASDAQ | |||
| 265.92 | 270.23 | 263.63 | +7.16 | +2.77% | 3.02M | NYSE | |||
| 316.91 | 318.45 | 306.51 | +16.54 | +5.51% | 23.99M | NASDAQ | |||
| 211.25 | 211.32 | 207.36 | +2.46 | +1.18% | 967.34K | NASDAQ | |||
| 3,527.00 | 3,531.90 | 3,466.69 | +99.63 | +2.91% | 1.17M | NASDAQ | |||
| 53.15 | 55.00 | 52.66 | +2.16 | +4.24% | 47.11M | NASDAQ | |||
| 52.15 | 52.50 | 50.41 | +0.67 | +1.30% | 14.77M | NYSE | |||
| 124.78 | 129.45 | 124.20 | +1.18 | +0.96% | 18.70M | NYSE | |||
| 45.11 | 45.64 | 44.99 | 0.00 | 0.00% | 2.21M | NYSE | |||
| 32.88 | 34.52 | 32.68 | +0.54 | +1.65% | 29.71M | NYSE | |||
| 55.11 | 55.33 | 54.85 | +0.20 | +0.36% | 9.78M | NYSE | |||
| 19.46 | 19.85 | 19.08 | +0.66 | +3.52% | 17.35M | NYSE | |||
| 206.99 | 207.85 | 205.90 | +4.30 | +2.12% | 5.12M | NYSE |